NSCLC patients with a smoking history or tumors with smoking-related signatures had better response rates and survival outcomes with anti-PD-1 treatments than never smokers or those with tumors without smoking-related signatures [51,58]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.